GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » American Bio Medica Corp (OTCPK:ABMC) » Definitions » Asset Turnover

American Bio Medica (American Bio Medica) Asset Turnover : 0.17 (As of Mar. 2023)


View and export this data going back to . Start your Free Trial

What is American Bio Medica Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. American Bio Medica's Revenue for the three months ended in Mar. 2023 was $0.16 Mil. American Bio Medica's Total Assets for the quarter that ended in Mar. 2023 was $0.96 Mil. Therefore, American Bio Medica's Asset Turnover for the quarter that ended in Mar. 2023 was 0.17.

Asset Turnover is linked to ROE % through Du Pont Formula. American Bio Medica's annualized ROE % for the quarter that ended in Mar. 2023 was -538.01%. It is also linked to ROA % through Du Pont Formula. American Bio Medica's annualized ROA % for the quarter that ended in Mar. 2023 was 780.50%.


American Bio Medica Asset Turnover Historical Data

The historical data trend for American Bio Medica's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Bio Medica Asset Turnover Chart

American Bio Medica Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.44 1.61 2.07 1.17 0.58

American Bio Medica Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.13 0.17 0.14 0.17

Competitive Comparison of American Bio Medica's Asset Turnover

For the Diagnostics & Research subindustry, American Bio Medica's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Bio Medica's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, American Bio Medica's Asset Turnover distribution charts can be found below:

* The bar in red indicates where American Bio Medica's Asset Turnover falls into.



American Bio Medica Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

American Bio Medica's Asset Turnover for the fiscal year that ended in Dec. 2022 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2022 )/( (Total Assets (A: Dec. 2021 )+Total Assets (A: Dec. 2022 ))/ count )
=0.913/( (1.883+1.269)/ 2 )
=0.913/1.576
=0.58

American Bio Medica's Asset Turnover for the quarter that ended in Mar. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2023 )/( (Total Assets (Q: Dec. 2022 )+Total Assets (Q: Mar. 2023 ))/ count )
=0.164/( (1.269+0.659)/ 2 )
=0.164/0.964
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


American Bio Medica  (OTCPK:ABMC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

American Bio Medica's annulized ROE % for the quarter that ended in Mar. 2023 is

ROE %**(Q: Mar. 2023 )
=Net Income/Total Stockholders Equity
=7.524/-1.3985
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(7.524 / 0.656)*(0.656 / 0.964)*(0.964/ -1.3985)
=Net Margin %*Asset Turnover*Equity Multiplier
=1146.95 %*0.6805*-0.6893
=ROA %*Equity Multiplier
=780.50 %*-0.6893
=-538.01 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

American Bio Medica's annulized ROA % for the quarter that ended in Mar. 2023 is

ROA %(Q: Mar. 2023 )
=Net Income/Total Assets
=7.524/0.964
=(Net Income / Revenue)*(Revenue / Total Assets)
=(7.524 / 0.656)*(0.656 / 0.964)
=Net Margin %*Asset Turnover
=1146.95 %*0.6805
=780.50 %

Note: The Net Income data used here is four times the quarterly (Mar. 2023) net income data. The Revenue data used here is four times the quarterly (Mar. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


American Bio Medica Asset Turnover Related Terms

Thank you for viewing the detailed overview of American Bio Medica's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


American Bio Medica (American Bio Medica) Business Description

Traded in Other Exchanges
N/A
Address
122 Smith Road, Kinderhook, New York, NY, USA, 12106
American Bio Medica Corp is a us-based company engaged in manufacturing and selling lateral flow immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids at the point of collection. It also manufactures and sells drug testing products and provides bulk test strip manufacturing services to unaffiliated third parties on a contract basis. The company offers few urine tests which include Rapid Drug Screen, RDS InCup, Rapid TOX, and Rapid TOX Cup II. Its target customer includes workplace, government, corrections, clinical and educational markets. Geographically, it derives a majority of revenue from the United States.
Executives
Stuart Steinberg 10 percent owner 85 BELLEVUE AVENUE, RYE NY 10580
John J Moroney 10 percent owner 118 PEGASUS DR., JUPITER FL 33477
Chaim Davis director 2601 PINE TREE DRIVE, MIAMI BEACH FL 33140
Peter Jerome director 7 RIDGECREST AVE, LATHAM NY 12110
Diane Generous director 122 SMITH ROAD, KINDERHOOK NY 12106
Melissa A Waterhouse officer: EVP, CCO, CORP SEC AMERICAN BIO MEDICA CORPORATION, 122 SMITH ROAD, KINDERHOOK NY 12106
Mp Biomedicals Llc 10 percent owner 3 HUTTON CENTRE DRIVE, SUITE 100, SANTA ANA CA 92707
Douglas Casterlin officer: Executive Vice President C/O MELISSA A. WATERHOUSE/ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Jean Neff director C/O ABMC, 122 SMITH ROAD, KINDERHOOK NY 12106
Stefan Parker officer: Chief Financial Officer 122 SMITH ROAD, KINDERHOOK NY 12106
Carl A Florio director C/O HUDSON RIVER BANK & TRUST CO, PO BOX 76, HUDSON NY 12534
Stan Cipkowski director 300 S LAKE DR, STE 340, FISHKILL NY 12553
Anthony G Costantino director 122 SMITH ROAD, KINDERHOOK NY 12106
Edmund M Jaskiewicz director, officer: President
Richard Koskey director C/O ABMC 122 SMITH ROAD, 122 SMITH ROAD, KINDERHOOK NY 12106

American Bio Medica (American Bio Medica) Headlines

From GuruFocus

ABMC Reports First Quarter 2018 Results

By ACCESSWIRE AccessWire 04-12-2019

ABMC Reports First Quarter 2021 Results

By ACCESSWIRE ACCESSWIRE 05-21-2021

ABMC Uplists to the OTCQB Venture Market

By ACCESSWIRE ACCESSWIRE 12-02-2020

ABMC Distributes Rapid Antigen Test For Covid-19

By ACCESSWIRE ACCESSWIRE 12-14-2020

ABMC Reports Third Quarter 2021 Results

By ACCESSWIRE ACCESSWIRE 11-18-2021

ABMC Reports Second Quarter 2021 Results

By ACCESSWIRE ACCESSWIRE 08-18-2021

ABMC Reports First Quarter 2020 Results

By ACCESSWIRE ACCESSWIRE 08-01-2020